Follow up of lung transplant recipients using an electronic nose

Lung transplantation is the only available treatment for some end-stage lung diseases. However, patients following lung transplantation need tight control to prevent serious complications, but mainly invasive techniques are available. An electronic nose is a non-invasive way to measure exhaled volatiles. In this study we investigated the potential of electronic nose measurements in lung transplant patients and compared the ‘breathprint’ with clinical parameters. Sixteen patients with lung transplant and 33 healthy subjects participated in the study. Exhaled breath was collected; laboratory tests and lung function measurements were carried out. Breath samples were processed by an electronic nose, analysed using principal component analysis and compared to blood (CRP, tacrolimus) and lung function parameters. Significant differences were found in exhaled breath volatile compound pattern between healthy subjects and lung transplant recipients. The plasma level of tacrolimus showed significant relationship with ‘breathprint’ in lung transplanted patients. Patients living with transplanted lungs can be discriminated from healthy subjects by exhaled breath volatile organic compounds’ profile. Treatment after lung transplantation needs to be taken into consideration when using an electronic nose as medication may have profound influence on breathprints.

[1]  P. Artemiadis,et al.  The role of muscle synergies in myoelectric control: trends and challenges for simultaneous multifunction control , 2014, Journal of neural engineering.

[2]  Sue Francis,et al.  Physiological measurements using ultra-high field fMRI: a review , 2014, Physiological measurement.

[3]  A. Dzien,et al.  Dependence of exhaled breath composition on exogenous factors, smoking habits and exposure to air pollutants , 2012, Journal of breath research.

[4]  G. Snell,et al.  Immunosuppression for Lung Transplantation , 2012, Drugs.

[5]  Deborah H Yates,et al.  A breath test for malignant mesothelioma using an electronic nose , 2011, European Respiratory Journal.

[6]  M P van der Schee,et al.  External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  Ildiko Horvath,et al.  Exercise changes volatiles in exhaled breath assessed by an electronic nose. , 2011, Acta physiologica Hungarica.

[8]  Zsofia Lazar,et al.  Exhaled breath volatile alterations in pregnancy assessed with electronic nose , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[9]  S. Palmer,et al.  Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. , 2011, Chest.

[10]  Deborah H Yates,et al.  Non-invasive assessment of exhaled biomarkers in lung transplantation , 2011, Journal of breath research.

[11]  I. Barta,et al.  Exhaled Breath Condensate pH in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome , 2011, Transplantation.

[12]  P. Ueberfuhr,et al.  Usefulness of Exhaled Nitric Oxide to Guide Risk Stratification for Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  I. Horváth,et al.  Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study. , 2010, American journal of respiratory and critical care medicine.

[14]  Ildikó Horváth,et al.  Exhaled carbon monoxide in airway diseases: from research findings to clinical relevance , 2010, Journal of breath research.

[15]  P. Zanen,et al.  Systemic and exhaled cytokine and chemokine profiles are associated with the development of bronchiolitis obliterans syndrome. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  J. Hohlfeld,et al.  Independent Information of Nonspecific Biomarkers in Exhaled Breath Condensate , 2010, Respiration.

[17]  P. Danaher,et al.  Effect of influenza vaccination on oxidative stress products in breath , 2010, Journal of breath research.

[18]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II , 2010, Clinical pharmacokinetics.

[19]  W. Wallace,et al.  Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment. , 2010, Seminars in respiratory and critical care medicine.

[20]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[21]  J. Pleil.  Influence of systems biology response and environmental exposure level on between-subject variability in breath and blood biomarkers , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[22]  I. Horváth,et al.  Exhaled biomarkers in lung cancer , 2009, European Respiratory Journal.

[23]  Robin Vos,et al.  Exhaled Carbon Monoxide as a Noninvasive Marker of Airway Neutrophilia After Lung Transplantation , 2009, Transplantation.

[24]  J. Egan,et al.  Infections relevant to lung transplantation. , 2009, Proceedings of the American Thoracic Society.

[25]  M. Woo.  Overview of Lung Transplantation , 2008, Clinical reviews in allergy & immunology.

[26]  I. Horváth,et al.  Variability of Exhaled Breath Condensate pH in Lung Transplant Recipients , 2007, Respiration.

[27]  D. Yates,et al.  Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. , 2007, American journal of respiratory and critical care medicine.

[28]  G. Snell,et al.  Immunosuppression for lung transplantation: evidence to date. , 2007, Drugs.

[29]  K. Iwasaki.  Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. , 2007, Drug metabolism and pharmacokinetics.

[30]  Zulfiqur Ali,et al.  Data analysis for electronic nose systems , 2006 .

[31]  G. Verleden,et al.  The pH of Exhaled Breath Condensate of Patients with Allograft Rejection After Lung Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  R. Diasio,et al.  The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil , 2006, Clinical Cancer Research.

[33]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[34]  Erica R Thaler,et al.  Correlation of Pneumonia Score with Electronic Nose Signature: A Prospective Study , 2005, The Annals of otology, rhinology, and laryngology.

[35]  I. Horváth,et al.  Pulmonary infections increase exhaled nitric oxide in lung transplant recipients: a longitudinal study , 2005, Clinical transplantation.

[36]  Peter Elsner,et al.  Smelling Renal Dysfunction via Electronic Nose , 2005, Annals of Biomedical Engineering.

[37]  Kohji Mitsubayashi,et al.  Bioelectronic sniffers for ethanol and acetaldehyde in breath air after drinking. , 2005, Biosensors & bioelectronics.

[38]  Zulfiqur Ali,et al.  Chemical Sensors for Electronic Nose Systems , 2005 .

[39]  N. Lewis.  Comparisons between mammalian and artificial olfaction based on arrays of carbon black-polymer composite vapor detectors. , 2004, Accounts of chemical research.

[40]  M. Phillips,et al.  Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  M. Phillips,et al.  Increased breath biomarkers of oxidative stress in diabetes mellitus. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[42]  C. Lau,et al.  Current status of lung transplantation , 2003, European Respiratory Journal.

[43]  J. Orens,et al.  Patterns and significance of exhaled-breath biomarkers in lung transplant recipients with acute allograft rejection. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[44]  G. Snell,et al.  Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. , 2000, American journal of respiratory and critical care medicine.

[45]  G. Snell,et al.  In stable lung transplant recipients, exhaled nitric oxide levels positively correlate with airway neutrophilia and bronchial epithelial iNOS. , 1999, American journal of respiratory and critical care medicine.

[46]  R. Cataneo,et al.  Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study , 1999, The Lancet.

[47]  J. Hardy,et al.  The first lung transplant in man (1963) and the first heart transplant in man (1964). , 1999, Transplantation proceedings.

[48]  Arthur S Slutsky,et al.  Exhaled nitric oxide in human lung transplantation. A noninvasive marker of acute rejection. , 1998, American journal of respiratory and critical care medicine.

[49]  E. Schaller,et al.  ‘Electronic Noses’ and Their Application to Food , 1998 .